Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 3

Active, not recruiting

Conditions: DS Stage I Multiple Myeloma
Smoldering Multiple Myeloma
DS Stage II Multiple Myeloma
DS Stage III Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Placebo Administration

First Posted Date: 2005-06-14

Last Posted Date: 2024-11-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 460

Registration Number: NCT00114101

Locations: 🇺🇸
Carle BroMenn Medical Center, Normal, Illinois, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 137 locations

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Sarcoma
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2005-06-03

Last Posted Date: 2013-07-18

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 10

Registration Number: NCT00112645

Locations: 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1

Completed

Conditions: Smoldering Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Radiation: total marrow irradiation
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Biological: filgrastim
Genetic: fluorescence in situ hybridization
Genetic: cytogenetic analysis
Drug: cyclophosphamide
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: lenalidomide

First Posted Date: 2005-06-03

Last Posted Date: 2021-03-01

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 54

Registration Number: NCT00112827

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2005-03-04

Last Posted Date: 2016-12-15

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT00104975

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00103298

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: isolated perfusion
Drug: melphalan

First Posted Date: 2004-11-09

Last Posted Date: 2013-10-23

Lead Sponsor: Delcath Systems Inc.

Target Recruit Count: 56

Registration Number: NCT00096083

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-09-13

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003353

Locations: 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States

and more 14 locations

Chemotherapy in Treating Children With Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

First Posted Date: 2004-09-01

Last Posted Date: 2024-11-20

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Registration Number: NCT00002730

Locations: 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 1 locations